Literature DB >> 34926226

Systematic review and meta-analysis of the efficacy of general anesthesia combined with a thoracic nerve block in modified breast cancer surgery.

Juan Liao1, Meiting Li2, Jiaqi Gan3,4, Jie Xiao2,4, Guilin Xiang2,4, Xizhi Ding2, Rong Jiang2, Peng Li2.   

Abstract

BACKGROUND: Breast cancer is a malignant tumor disease that poses a significant threat to women's health. In recent years, the incidence of breast cancer in China has been increasing. This report aims to explore the effects of general anesthesia combined with a thoracic nerve block in modified breast cancer surgery.
METHODS: A computer-based search of PubMed, Web of Science, Embase, and the Cochrane Library was performed to identify randomized controlled studies on breast cancer, general anesthesia combined with a thoracic nerve block, modified breast cancer surgery, and other breast cancer treatments. Further search criteria included postoperative pain score, postoperative morphine equivalents given 24 hours after surgery, and operation duration. After an initial selection process, the studies were evaluated using the Jadad scale and the Cochrane Handbook for Systematic Reviews of Interventions to assess their suitability for inclusion in the subsequent meta-analysis of the experimental data, which was carried out using RevMan 5.3.
RESULTS: A total of 8 studies comprising a total of 624 patients were selected for inclusion in this report. According to the meta-analysis, the analytical structure of the thoracic nerve group and the control group had a mean difference (MD) of -1.27 [95% confidence interval (CI): -1.68 to -0.86], the structure of the statistical test was Z=6.08 (P<0.00001), the MD of the total analysis structure of morphine equivalents was -2.71 (95% CI: -4.98 to -0.44), and the statistical test structure was Z=2.34 (P=0.02). DISCUSSION: General anesthesia combined with a thoracic nerve block in breast cancer surgery may effectively improve postoperative pain in patients and reduce the need for analgesic drugs. However, the outcome indicators included in this study are not sufficient. It is necessary to increase both the sample size and the number of outcome indicators to provide further theoretical evidence for the subsequent application of thoracic nerve block in modified breast cancer surgery. 2021 Gland Surgery. All rights reserved.

Entities:  

Keywords:  General anesthesia; complex thoracic nerve block; modified breast cancer surgery; postmastectomy pain syndrome (PMPS)

Year:  2021        PMID: 34926226      PMCID: PMC8637070          DOI: 10.21037/gs-21-719

Source DB:  PubMed          Journal:  Gland Surg        ISSN: 2227-684X


  32 in total

1.  Comparison of the effects of modified pectoral nerve block and erector spinae plane block on postoperative opioid consumption and pain scores of patients after radical mastectomy surgery: A prospective, randomized, controlled trial.

Authors:  Başak Altıparmak; Melike Korkmaz Toker; Ali İhsan Uysal; Mustafa Turan; Semra Gümüş Demirbilek
Journal:  J Clin Anesth       Date:  2018-11-03       Impact factor: 9.452

2.  Postmastectomy pain syndrome after preoperative stellate ganglion block: a randomized controlled trial.

Authors:  Ahmed S Salman; Dina N Abbas; Mai M Elrawas; Mahmoud A Kamel; Ahmed M Mohammed; Ahmed H Abouel Soud; Ahmed S Abdelgalil
Journal:  Minerva Anestesiol       Date:  2021-05-03       Impact factor: 3.051

3.  Pectoral nerves I and II blocks in multimodal analgesia for breast cancer surgery: a randomized clinical trial.

Authors:  Ghada Mohammad Nabih Bashandy; Dina Nabil Abbas
Journal:  Reg Anesth Pain Med       Date:  2015 Jan-Feb       Impact factor: 6.288

4.  Prospective double blind randomized placebo-controlled clinical trial of the pectoral nerves (Pecs) block type II.

Authors:  Barbara Versyck; Geert-Jan van Geffen; Patrick Van Houwe
Journal:  J Clin Anesth       Date:  2017-04-19       Impact factor: 9.452

5.  Impact of pectoral nerve block on postoperative pain and quality of recovery in patients undergoing breast cancer surgery: A randomised controlled trial.

Authors:  Yoshinori Kamiya; Miki Hasegawa; Takayuki Yoshida; Misako Takamatsu; Yu Koyama
Journal:  Eur J Anaesthesiol       Date:  2018-03       Impact factor: 4.330

Review 6.  Screening for breast cancer in 2018-what should we be doing today?

Authors:  J M Seely; T Alhassan
Journal:  Curr Oncol       Date:  2018-06-13       Impact factor: 3.677

7.  Efficacy of pectoral nerve block type II versus thoracic paravertebral block for analgesia in breast cancer surgery.

Authors:  Volodymyrovych Volodymyr Martsiniv; Anatoliiovych Oleg Loskutov; Mykolaiovych Andriy Strokan; Mykolaiovych Maksim Pylypenko; Volodymyrovych Mihailo Bondar
Journal:  Klin Onkol       Date:  2020

Review 8.  Persistent Post-Mastectomy Pain: Risk Factors and Current Approaches to Treatment.

Authors:  Raymond C Tait; Kim Zoberi; McKenzie Ferguson; Kimberly Levenhagen; Rebecca A Luebbert; Kevin Rowland; Gretchen B Salsich; Christopher Herndon
Journal:  J Pain       Date:  2018-06-30       Impact factor: 5.820

9.  Benefits in radical mastectomy protocol: a randomized trial evaluating the use of regional anesthesia.

Authors:  Marcio Matsumoto; Eva M Flores; Pedro P Kimachi; Flavia V Gouveia; Mayra A Kuroki; Alfredo C S D Barros; Marcelo M C Sampaio; Felipe E M Andrade; João Valverde; Eduardo F Abrantes; Claudia M Simões; Rosana L Pagano; Raquel C R Martinez
Journal:  Sci Rep       Date:  2018-05-18       Impact factor: 4.379

10.  Efficacy of Pectoral Nerve Block Type II for Breast-Conserving Surgery and Sentinel Lymph Node Biopsy: A Prospective Randomized Controlled Study.

Authors:  Doo-Hwan Kim; Sooyoung Kim; Chan Sik Kim; Sukyung Lee; In-Gyu Lee; Hee Jeong Kim; Jong-Hyuk Lee; Sung-Moon Jeong; Kyu Taek Choi
Journal:  Pain Res Manag       Date:  2018-05-15       Impact factor: 3.037

View more
  1 in total

1.  Development and validation of an extended Cox prognostic model for patients with ER/PR+ and HER2- breast cancer: a retrospective cohort study.

Authors:  Yiqun Xie; Xizhou Li; Ying Wu; Wenting Cui; Yang Liu
Journal:  World J Surg Oncol       Date:  2022-10-12       Impact factor: 3.253

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.